Bruce Brockstein to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Bruce Brockstein has written about TOR Serine-Threonine Kinases.
Connection Strength
0.025
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.025
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.